Back Bay Life Science Report
Skupno trajanje:
14 h 03 min
A Capital Markets Outlook for 2025: 2024, A Year in Review
Back Bay Life Science Report
15:58
The Optimism of Bispecific Antibodies
Back Bay Life Science Report
26:39
Dynamics in Healthcare Focused Markets
Back Bay Life Science Report
20:49
From NASH to MASH: Current Market Dynamics in Hepatology
Back Bay Life Science Report
28:19
Key Considerations for a US Healthcare IPO
Back Bay Life Science Report
35:03
Drug Development in Obesity
Back Bay Life Science Report
26:56
The Current Dynamics in Capital Markets
Back Bay Life Science Report
22:25
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
Back Bay Life Science Report
37:34
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
Back Bay Life Science Report
25:52
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
Back Bay Life Science Report
25:26
Monthly Roundup of News from Healthcare Development
Back Bay Life Science Report
30:04
The Current and Future Landscape of Healthcare IPO Markets
Back Bay Life Science Report
23:41
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
Back Bay Life Science Report
24:43
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
Back Bay Life Science Report
25:54
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
Back Bay Life Science Report
29:03
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
Back Bay Life Science Report
28:35
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
Back Bay Life Science Report
37:16
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
Back Bay Life Science Report
28:01
The Promising Field of Targeted Protein Degraders (TPDs)
Back Bay Life Science Report
23:10
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
Back Bay Life Science Report
29:44
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
Back Bay Life Science Report
29:42
The Evolving Regulatory Framework for Novel Medicines in the EU
Back Bay Life Science Report
25:53
The Commercial Potential of Optogenetic Therapies
Back Bay Life Science Report
23:14
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
Back Bay Life Science Report
22:12
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
Back Bay Life Science Report
25:51
Cell and Gene Therapy Investment Trends
Back Bay Life Science Report
19:33
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
Back Bay Life Science Report
26:33
Remote Patient Monitoring
Back Bay Life Science Report
26:30
New Drug Pricing and Market Access
Back Bay Life Science Report
26:25
The Question of Investment in Antimicrobials
Back Bay Life Science Report
25:25
Life Science SPACs: A Forward Look at this Evolving Asset Class
Back Bay Life Science Report
25:17
Gene Therapies: What’s to Come as The Industry Moves Forward
Back Bay Life Science Report
21:52
